Artera Presents Multiple ASCO 2026 Abstracts on Multimodal AI (MMAI) Risk Stratification and Treatment Decisions in Cancer
Validation of MMAI in node-positive HR+ breast cancer to determine chemotherapy benefit Concordance analysis between MMAI and [...]
Artera Expands Its Validated Multimodal AI Platform to Metastatic Hormone‑Sensitive Prostate Cancer (mHSPC)
First digital pathology-based test to provide individual risk estimates to help inform treatment planning in mHSPC SAN FRANCI [...]
Artera Receives U.S. FDA Clearance for ArteraAI Breast, Expanding Its AI Platform to Breast Cancer
Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, today announ [...]
Artera Secures CE Marking for Its AI Prostate and Breast Cancer Assays, Unlocking Global Expansion
Dual regulatory milestones establish Artera as a global AI leader in precision oncology SAN FRANCISCO, April 21, 2026— Artera [...]
Artera Debuts ArteraAI Prostate Test (Post‑RP), Expanding its Oncology Portfolio
-Artera, a developer of multimodal AI-based prognostic and predictive cancer tests, today announced the commercial launch of [...]
Artera Unveils Data Demonstrating Prognostic and Predictive Utility in Breast Cancer at SABCS 2025
Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, today announ [...]
Journal of Clinical Oncology Publishes Significant Evidence in Advancing Racial Equity in Cancer Care Through Artera’s Multimodal AI Model
The validation study shows no evidence of algorithmic bias. The development of the model may help mitigate the risk of racial [...]
Artera Unveils Four Presentations at ASTRO 2025 Illustrating its Multimodal Artificial Intelligence (MMAI) Platform’s Scalability, Speed, and Potential to Personalize Treatment Decisions for Multiple Cancers
SAN FRANCISCO--(BUSINESS WIRE)--Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predi [...]
Artera Receives U.S. FDA De Novo Marketing Authorization for AI-Digital Pathology Software Revolutionizing Prostate Cancer Care
Novel risk stratification tool advances the frontier of precision oncology by providing access to insights informing critical [...]